JP2017512184A - アミノ置換されたイソチアゾール類 - Google Patents
アミノ置換されたイソチアゾール類 Download PDFInfo
- Publication number
- JP2017512184A JP2017512184A JP2016548682A JP2016548682A JP2017512184A JP 2017512184 A JP2017512184 A JP 2017512184A JP 2016548682 A JP2016548682 A JP 2016548682A JP 2016548682 A JP2016548682 A JP 2016548682A JP 2017512184 A JP2017512184 A JP 2017512184A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- amino
- thiazole
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 C*=*C(*)=N*=* Chemical compound C*=*C(*)=N*=* 0.000 description 7
- XKVUYEYANWFIJX-UHFFFAOYSA-N Cc1ccn[nH]1 Chemical compound Cc1ccn[nH]1 XKVUYEYANWFIJX-UHFFFAOYSA-N 0.000 description 2
- VWKLYQRLHOHVIH-AWEZNQCLSA-N CC(C)(C#N)OC(N1C[C@@H](COc(cc(cc2)NC(c3c(N)[s]nc3C=C)=O)c2F)CCC1)=O Chemical compound CC(C)(C#N)OC(N1C[C@@H](COc(cc(cc2)NC(c3c(N)[s]nc3C=C)=O)c2F)CCC1)=O VWKLYQRLHOHVIH-AWEZNQCLSA-N 0.000 description 1
- SKFZCPKXUYABIJ-UHFFFAOYSA-N CC(C)(C)OC(N(C)CCOc(nc1)ccc1[IH][NH+]([O-])[O-])=O Chemical compound CC(C)(C)OC(N(C)CCOc(nc1)ccc1[IH][NH+]([O-])[O-])=O SKFZCPKXUYABIJ-UHFFFAOYSA-N 0.000 description 1
- UDURZOQOBZQLGK-ZDUSSCGKSA-N CC(C)(C)OC(N(CC1)C[C@H]1Oc1cc(NC(c2c(N)[s]nc2C)=O)ccc1F)=O Chemical compound CC(C)(C)OC(N(CC1)C[C@H]1Oc1cc(NC(c2c(N)[s]nc2C)=O)ccc1F)=O UDURZOQOBZQLGK-ZDUSSCGKSA-N 0.000 description 1
- LJSXYOHIIBFVEI-UHFFFAOYSA-N CC(C)(C)OC(N1CC(COc(nc2)ccc2[N+]([O-])=O)CC1)=O Chemical compound CC(C)(C)OC(N1CC(COc(nc2)ccc2[N+]([O-])=O)CC1)=O LJSXYOHIIBFVEI-UHFFFAOYSA-N 0.000 description 1
- RJOVNVHPKPOEAE-UHFFFAOYSA-N CC(N(CC1)CCC1Oc(cc1)ncc1NC(c1c(Nc2nc(cccc3)c3nc2)[s]nc1C)=O)=O Chemical compound CC(N(CC1)CCC1Oc(cc1)ncc1NC(c1c(Nc2nc(cccc3)c3nc2)[s]nc1C)=O)=O RJOVNVHPKPOEAE-UHFFFAOYSA-N 0.000 description 1
- VLXIPLSFZOMRRT-UHFFFAOYSA-N CC(Nc(nc1)ccc1NC(c1c(N)[s]nc1C)=O)=O Chemical compound CC(Nc(nc1)ccc1NC(c1c(N)[s]nc1C)=O)=O VLXIPLSFZOMRRT-UHFFFAOYSA-N 0.000 description 1
- DNCBHXVFJBDZBW-UHFFFAOYSA-N CC1NSC(Nc(nc2)ccc2C#N)=C1C(Nc(cc1)cnc1OC1CCN(CC(F)(F)F)CC1)=O Chemical compound CC1NSC(Nc(nc2)ccc2C#N)=C1C(Nc(cc1)cnc1OC1CCN(CC(F)(F)F)CC1)=O DNCBHXVFJBDZBW-UHFFFAOYSA-N 0.000 description 1
- UCAHRRAAMMMTSS-UHFFFAOYSA-N CCCC(CCN)Oc(cc1)ncc1NC(c1c(Nc2ncc(C(F)(F)F)nc2)[s]nc1C)=O Chemical compound CCCC(CCN)Oc(cc1)ncc1NC(c1c(Nc2ncc(C(F)(F)F)nc2)[s]nc1C)=O UCAHRRAAMMMTSS-UHFFFAOYSA-N 0.000 description 1
- NNUCNSPVDXDZIA-UHFFFAOYSA-N Cc1n[s]c(N)c1C(Nc(cc1)cnc1Nc(cc1F)ccc1F)=O Chemical compound Cc1n[s]c(N)c1C(Nc(cc1)cnc1Nc(cc1F)ccc1F)=O NNUCNSPVDXDZIA-UHFFFAOYSA-N 0.000 description 1
- VHGDILASFHRAIA-UHFFFAOYSA-N Cc1n[s]c(N)c1C(Nc1cccc(C(OC)=O)c1)=O Chemical compound Cc1n[s]c(N)c1C(Nc1cccc(C(OC)=O)c1)=O VHGDILASFHRAIA-UHFFFAOYSA-N 0.000 description 1
- ISXLXBCSQFUBBF-UHFFFAOYSA-N Cc1n[s]c(NCc2nc3c(C(F)(F)F)cccc3[s]2)c1C(Nc(cc1)cnc1OCCO)=O Chemical compound Cc1n[s]c(NCc2nc3c(C(F)(F)F)cccc3[s]2)c1C(Nc(cc1)cnc1OCCO)=O ISXLXBCSQFUBBF-UHFFFAOYSA-N 0.000 description 1
- SOXVXWJWQXQBLK-UHFFFAOYSA-N Cc1n[s]c(Nc2cc(C#N)ccn2)c1C(Nc(cc1)cnc1OCCCNCC(F)F)=O Chemical compound Cc1n[s]c(Nc2cc(C#N)ccn2)c1C(Nc(cc1)cnc1OCCCNCC(F)F)=O SOXVXWJWQXQBLK-UHFFFAOYSA-N 0.000 description 1
- DGSTVUATWGUPRU-UHFFFAOYSA-N Cc1n[s]c(Nc2nc(cccc3)c3nc2)c1C(Nc1cc(C(NC(CCC(N)=O)C(O)=O)=O)ccc1)O Chemical compound Cc1n[s]c(Nc2nc(cccc3)c3nc2)c1C(Nc1cc(C(NC(CCC(N)=O)C(O)=O)=O)ccc1)O DGSTVUATWGUPRU-UHFFFAOYSA-N 0.000 description 1
- TVRSTVTWYZZDKM-HNNXBMFYSA-N Cc1n[s]c(Nc2ncc(C(F)(F)F)nc2)c1C(Nc(cc1OC[C@@H]2CN(CCC(F)(F)F)CCC2)ccc1F)=O Chemical compound Cc1n[s]c(Nc2ncc(C(F)(F)F)nc2)c1C(Nc(cc1OC[C@@H]2CN(CCC(F)(F)F)CCC2)ccc1F)=O TVRSTVTWYZZDKM-HNNXBMFYSA-N 0.000 description 1
- LLBIDJNBLOKREX-UHFFFAOYSA-N Cc1n[s]c(Nc2ncc(C(F)(F)F)nc2)c1C(Nc(cn1)ccc1OCC1CN(CCF)CC1)=O Chemical compound Cc1n[s]c(Nc2ncc(C(F)(F)F)nc2)c1C(Nc(cn1)ccc1OCC1CN(CCF)CC1)=O LLBIDJNBLOKREX-UHFFFAOYSA-N 0.000 description 1
- UGARJNIKKUWTJC-UONOGXRCSA-N Cc1n[s]c(Nc2ncc(C(F)(F)F)nc2)c1C(Nc(cn1)ccc1O[C@H](CN(CCC(F)(F)F)C1)[C@H]1F)=O Chemical compound Cc1n[s]c(Nc2ncc(C(F)(F)F)nc2)c1C(Nc(cn1)ccc1O[C@H](CN(CCC(F)(F)F)C1)[C@H]1F)=O UGARJNIKKUWTJC-UONOGXRCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14153031 | 2014-01-29 | ||
| EP14153031.1 | 2014-01-29 | ||
| EP14178680.6A EP2980088A1 (en) | 2014-07-28 | 2014-07-28 | Amino-substituted isothiazoles |
| EP14178680.6 | 2014-07-28 | ||
| PCT/EP2015/051440 WO2015113920A1 (en) | 2014-01-29 | 2015-01-26 | Amino-substituted isothiazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017512184A true JP2017512184A (ja) | 2017-05-18 |
| JP2017512184A5 JP2017512184A5 (cg-RX-API-DMAC7.html) | 2018-03-01 |
Family
ID=52434789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548682A Withdrawn JP2017512184A (ja) | 2014-01-29 | 2015-01-26 | アミノ置換されたイソチアゾール類 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20170334899A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3099682A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017512184A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106414435A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2937989A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015113920A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN117777121A (zh) | 2016-10-24 | 2024-03-29 | 詹森药业有限公司 | 化合物及其用途 |
| MA47212A (fr) | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| JP2020515689A (ja) * | 2017-03-29 | 2020-05-28 | イーストマン ケミカル カンパニー | 位置選択的に置換されたセルロースエステル |
| EP3700934A4 (en) | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THESE COMPOUNDS |
| CN112312913B (zh) | 2018-03-23 | 2024-03-08 | 詹森药业有限公司 | 化合物和其用途 |
| SG11202108079RA (en) | 2019-01-24 | 2021-08-30 | Yumanity Therapeutics Inc | Compounds and uses thereof |
| MA55385A (fr) * | 2019-03-22 | 2022-01-26 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010007418A (es) * | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
| JP2013525290A (ja) * | 2010-04-15 | 2013-06-20 | ノバルティス アーゲー | Ｋｓｐ阻害剤としてのオキサゾールおよびチアゾール化合物 |
| JP2016506921A (ja) * | 2013-01-30 | 2016-03-07 | バイエル ファーマ アクチエンゲゼルシャフト | アミノ置換イソチアゾール |
-
2015
- 2015-01-26 US US15/115,274 patent/US20170334899A1/en not_active Abandoned
- 2015-01-26 EP EP15701759.1A patent/EP3099682A1/en not_active Withdrawn
- 2015-01-26 WO PCT/EP2015/051440 patent/WO2015113920A1/en not_active Ceased
- 2015-01-26 CN CN201580017711.2A patent/CN106414435A/zh active Pending
- 2015-01-26 CA CA2937989A patent/CA2937989A1/en not_active Abandoned
- 2015-01-26 JP JP2016548682A patent/JP2017512184A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20170334899A1 (en) | 2017-11-23 |
| EP3099682A1 (en) | 2016-12-07 |
| CA2937989A1 (en) | 2015-08-06 |
| CN106414435A (zh) | 2017-02-15 |
| WO2015113920A1 (en) | 2015-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3402795B1 (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
| AU2012350751B2 (en) | Substituted triazolopyridines and their use as TTK inhibitors | |
| JP2017512184A (ja) | アミノ置換されたイソチアゾール類 | |
| EP3319945B1 (en) | 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors | |
| US10138226B2 (en) | Benzimidazol-2-amines as MIDH1 inhibitors | |
| AU2016257302A1 (en) | Amido-substituted cyclohexane derivatives | |
| UA113280C2 (xx) | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
| EP3209660B1 (en) | 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors | |
| BR112017013148A2 (pt) | pirazolopiridinaminas como inibidores mknk1 e mknk2 | |
| WO2017055316A1 (en) | Amido-substituted azole compounds | |
| WO2015113927A1 (en) | Amino-substituted isothiazoles | |
| EP4602049A1 (en) | Sos1 inhibitors | |
| EP3172204A1 (en) | Amino-substituted isoxazoles | |
| EP3149003A1 (en) | Benzothiadiazolamines | |
| EP2977375A1 (en) | Amino-substituted isoxazoles | |
| EP2980088A1 (en) | Amino-substituted isothiazoles | |
| TW201326170A (zh) | 經取代之三唑并吡啶 | |
| EP2977377A1 (en) | Amino-substituted isoxazoles | |
| EP2977376A1 (en) | Amino-substituted isoxazoles | |
| HK1234390A1 (en) | Amino-substituted isothiazoles | |
| NZ625815B2 (en) | Substituted triazolopyridines and their use as ttk inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180116 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180116 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20180417 |